热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　亚盛医药-B（06855）早盘上涨5.07%，现报40.45港元，成交额7852.04万港元。

　　亚盛医药-B发布公告，公司原创1类新药奥雷巴替尼（商品名：耐立克®）获国家药品监督管理局（NMPA）药品审评中心（CDE）纳入“突破性治疗品种”名单，用于联合化疗一线治疗新诊断费城染色体阳性（Ph+）急性淋巴细胞白血病（ALL）患者。

　　据悉，这是耐立克®第三次获CDE纳入突破性治疗品种。此前，该品种分别于2021年3月和2023年6月获纳入突破性治疗品种，用于治疗一代和二代酪氨酸激酶抑制剂（TKI）耐药和/或不耐受的慢性期慢性髓性白血病（CML-CP）患者；及既往经过一线治疗的琥珀酸脱氢酶（succinate dehydrogenase， SDH）缺陷型胃肠道间质瘤（GIST）患者。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.